These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34153124)

  • 1. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
    Mattoo VY; Basnayake C; Connell WR; Ding N; Kamm MA; Lust M; Niewiadomski O; Thompson A; Wright EK
    Aliment Pharmacol Ther; 2021 Aug; 54(3):249-266. PubMed ID: 34153124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary.
    Kósa F; Kunovszki P; Borsi A; Iliás Á; Palatka K; Szamosi T; Vincze Á; Molnár T; Lakatos PL
    Dig Liver Dis; 2020 Mar; 52(3):274-280. PubMed ID: 31669077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotics for induction and maintenance of remission in Crohn's disease.
    Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: A systematic review.
    Martín-García P; Alonso-Arroyo A; Catalá-López F
    Med Clin (Barc); 2023 Jun; 160(11):501-516. PubMed ID: 36967304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
    Billioud V; Sandborn WJ; Peyrin-Biroulet L
    Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
    Papamichael K; Jairath V; Zou G; Cohen B; Ritter T; Sands B; Siegel C; Valentine J; Smith M; Vande Casteele N; Dubinsky M; Cheifetz A
    BMJ Open; 2022 Apr; 12(4):e057656. PubMed ID: 35365535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
    Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
    J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab.
    Restellini S; Chao CY; Lakatos PL; Aruljothy A; Aziz H; Kherad O; Bitton A; Wild G; Afif W; Bessissow T
    Inflamm Bowel Dis; 2018 Jun; 24(7):1531-1538. PubMed ID: 29668893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
    Osamura A; Suzuki Y
    Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients.
    Greener T; Boland K; Milgrom R; Ben-Bassat O; Steinhart AH; Silverberg MS; Narula N
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1274-1279. PubMed ID: 34402466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months.
    Little RD; Chu IE; Ward MG; Sparrow MP
    Dig Dis Sci; 2022 Jan; 67(1):259-262. PubMed ID: 33763785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
    Faleck DM; Shmidt E; Huang R; Katta LG; Narula N; Pinotti R; Suarez-Farinas M; Colombel JF
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):238-245.e4. PubMed ID: 32569749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
    Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
    Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response.
    Ghaly S; Costello S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; Antoniades S; Headon B; Connor S; Lawrance IC; Sparrow M; Walsh AJ; Andrews JM;
    Intern Med J; 2015 Feb; 45(2):170-7. PubMed ID: 25370691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.